1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1736-1788. PMID:
30496103
2. Gaziano TA, Prabhakaran D, Gaziano JM. Global burden of cardiovascular disease. In: Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Braunwald’s heart disease: a textbook of cardiovascular medicine. 10th ed. Philadelphia: Saunders; 2015. p 1-20.
3. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011;123:933-944. PMID:
21262990
5. Forouzanfar MH, Sepanlou SG, Shahraz S, Dicker D, Naghavi P, Pourmalek F, et al. Evaluating causes of death and morbidity in Iran, global burden of diseases, injuries, and risk factors study 2010. Arch Iran Med 2014;17:304-320. PMID:
24784860
6. Sadeghi M, Haghdoost AA, Bahrampour A, Dehghani M. Modeling the burden of cardiovascular diseases in Iran from 2005 to 2025: the impact of demographic changes. Iran J Public Health 2017;46:506-516. PMID:
28540267
8. Ng M, Freeman MK, Fleming TD, Robinson M, Dwyer-Lindgren L, Thomson B, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA 2014;311:183-192. PMID:
24399557
10. Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med 2013;368:341-350. PMID:
23343063
11. Office on Smoking and Health. The health consequences of involuntary exposure to tobacco smoke: a report of the Surgeon General. Atlanta: Centers for Disease Control and Prevention; 2006. p 509.
13. Nakamura K, Nakagawa H, Sakurai M, Murakami Y, Irie F, Fujiyoshi A, et al. Influence of smoking combined with another risk factor on the risk of mortality from coronary heart disease and stroke: pooled analysis of 10 Japanese cohort studies. Cerebrovasc Dis 2012;33:480-491. PMID:
22517421
14. Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet 2011;378:1297-1305.
15. Oza S, Thun MJ, Henley SJ, Lopez AD, Ezzati M. How many deaths are attributable to smoking in the United States? Comparison of methods for estimating smoking-attributable mortality when smoking prevalence changes. Prev Med 2011;52:428-433.
16. Mons U, Müezzinler A, Gellert C, Schöttker B, Abnet CC, Bobak M, et al. Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium. BMJ 2015;350:h1551.
17. Nance R, Delaney J, McEvoy JW, Blaha MJ, Burke GL, Navas-Acien A, et al. Smoking intensity (pack/day) is a better measure than pack-years or smoking status for modeling cardiovascular disease outcomes. J Clin Epidemiol 2017;81:111-119.
19. Azizi F, Madjid M, Rahmani M, Emami H, Mirmiran PA, Hadjipour R. Tehran Lipid and Glucose Study (TLGS): rationale and design. Iran J Endocrinol Metab 2000;2:77-86 (Persian).
20. Azizi F, Rahmani M, Emami H, Mirmiran PA, Hajipour R, Madjid M, et al. Cardiovascular risk factors in an Iranian urban population: Tehran Lipid and Glucose Study (phase 1). Soz Praventivmed 2002;47:408-426.
21. Khalili D, Azizi F, Asgari S, Zadeh-Vakili A, Momenan AA, Ghanbarian A, et al. Outcomes of a longitudinal population-based cohort study and pragmatic community trial: findings from 20 years of the Tehran Lipid and Glucose Study. Int J Endocrinol Metab 2018;16(4 Suppl):e84748. PMID:
30584434
24. Mirmiran P, Sherafat-Kazemzadeh R, Farahani SJ, Asghari G, Niroomand M, Momenan A, et al. Performance of different definitions of metabolic syndrome for children and adolescents in a 6-year follow-up: Tehran Lipid and Glucose Study (TLGS). Diabetes Res Clin Pract 2010;89:327-333.
25. Myint PK, Sinha S, Luben RN, Bingham SA, Wareham NJ, Khaw KT. Risk factors for first-ever stroke in the EPIC-Norfolk prospective population-based study. Eur J Cardiovasc Prev Rehabil 2008;15:663-669.
29. Gellert C, Schöttker B, Müller H, Holleczek B, Brenner H. Impact of smoking and quitting on cardiovascular outcomes and risk advancement periods among older adults. Eur J Epidemiol 2013;28:649-658.
31. Lv X, Sun J, Bi Y, Xu M, Lu J, Zhao L, et al. Risk of all-cause mortality and cardiovascular disease associated with secondhand smoke exposure: a systematic review and meta-analysis. Int J Cardiol 2015;199:106-115.
32. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003;290:86-97.
34. Cox LA Jr. Low-dose nonlinear effects of smoking on coronary heart disease risk. Dose Response 2012;10:219-232.
36. Law MR, Wald NJ. Environmental tobacco smoke and ischemic heart disease. Prog Cardiovasc Dis 2003;46:31-38.
37. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004;43:1731-1737.
38. Rahman MM, Laher I. Structural and functional alteration of blood vessels caused by cigarette smoking: an overview of molecular mechanisms. Curr Vasc Pharmacol 2007;5:276-292.
39. Armani C, Landini L Jr, Leone A. Molecular and biochemical changes of the cardiovascular system due to smoking exposure. Curr Pharm Des 2009;15:1038-1053.
40. Yamaguchi Y, Matsuno S, Kagota S, Haginaka J, Kunitomo M. Peroxynitrite-mediated oxidative modification of low-density lipoprotein by aqueous extracts of cigarette smoke and the preventive effect of fluvastatin. Atherosclerosis 2004;172:259-265.
41. Yamaguchi Y, Haginaka J, Morimoto S, Fujioka Y, Kunitomo M. Facilitated nitration and oxidation of LDL in cigarette smokers. Eur J Clin Invest 2005;35:186-193.
42. Yamaguchi Y, Matsuno S, Kagota S, Haginaka J, Kunitomo M. Oxidants in cigarette smoke extract modify low-density lipoprotein in the plasma and facilitate atherogenesis in the aorta of Watanabe heritable hyperlipidemic rabbits. Atherosclerosis 2001;156:109-117.
43. Bermudez EA, Rifai N, Buring JE, Manson JE, Ridker PM. Relation between markers of systemic vascular inflammation and smoking in women. Am J Cardiol 2002;89:1117-1119.
44. Zhang J, Liu Y, Shi J, Larson DF, Watson RR. Side-stream cigarette smoke induces dose-response in systemic inflammatory cytokine production and oxidative stress. Exp Biol Med (Maywood) 2002;227:823-829.
45. Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation 2005;111:2684-2698.
47. Pope CA 3rd, Burnett RT, Krewski D, Jerrett M, Shi Y, Calle EE, et al. Cardiovascular mortality and exposure to airborne fine particulate matter and cigarette smoke: shape of the exposure-response relationship. Circulation 2009;120:941-948.
48. Gellert C, Schöttker B, Brenner H. Smoking and all-cause mortality in older people: systematic review and meta-analysis. Arch Intern Med 2012;172:837-844.